Virtus ETF Advisers LLC Buys 214 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Virtus ETF Advisers LLC lifted its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,016 shares of the company’s stock after buying an additional 214 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Krystal Biotech were worth $316,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of KRYS. US Bancorp DE raised its stake in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after acquiring an additional 82 shares during the period. Summit Investment Advisors Inc. increased its holdings in shares of Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company’s stock valued at $407,000 after purchasing an additional 82 shares during the last quarter. Crossmark Global Holdings Inc. raised its position in shares of Krystal Biotech by 5.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after purchasing an additional 121 shares during the period. Envestnet Asset Management Inc. lifted its stake in shares of Krystal Biotech by 1.1% during the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company’s stock worth $1,822,000 after buying an additional 121 shares during the last quarter. Finally, Perigon Wealth Management LLC boosted its holdings in shares of Krystal Biotech by 1.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock worth $1,200,000 after buying an additional 123 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on KRYS shares. HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Jefferies Financial Group assumed coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target for the company. Chardan Capital increased their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. Finally, Citigroup upped their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Krystal Biotech has an average rating of “Buy” and an average target price of $220.00.

Krystal Biotech Stock Down 0.6 %

KRYS opened at $168.06 on Monday. Krystal Biotech, Inc. has a twelve month low of $141.72 and a twelve month high of $219.34. The stock has a market capitalization of $4.86 billion, a price-to-earnings ratio of 56.21 and a beta of 0.75. The company has a 50-day simple moving average of $176.37 and a 200 day simple moving average of $171.56.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same quarter last year, the business posted $0.30 EPS. The firm’s revenue for the quarter was up 116.4% on a year-over-year basis. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Activity

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).